Inspire Medical Systems (NYSE:INSP) Price Target Raised to $54.00

Inspire Medical Systems (NYSE:INSP) had its price target upped by Truist Financial from $50.00 to $54.00 in a research note issued to investors on Thursday, Marketbeat reports. Truist Financial currently has a hold rating on the stock.

A number of other equities research analysts have also recently weighed in on INSP. Piper Sandler cut shares of Inspire Medical Systems from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $85.00 to $55.00 in a research report on Tuesday, May 5th. Zacks Research upgraded shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Robert W. Baird lowered their price objective on shares of Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating for the company in a research report on Tuesday, May 5th. Royal Bank Of Canada downgraded shares of Inspire Medical Systems from a “sector perform” rating to a “buy” rating in a report on Monday, June 15th. Finally, Mizuho cut their target price on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $81.26.

Inspire Medical Systems Trading Down 2.0%

NYSE INSP opened at $50.53 on Thursday. The stock has a market cap of $1.46 billion, a PE ratio of 11.25, a P/E/G ratio of 5.12 and a beta of 0.71. Inspire Medical Systems has a twelve month low of $38.91 and a twelve month high of $147.03. The stock has a fifty day simple moving average of $44.36 and a 200-day simple moving average of $58.80.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The firm had revenue of $204.58 million during the quarter, compared to the consensus estimate of $200.04 million. During the same period last year, the company earned $0.10 EPS. The company’s quarterly revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Research analysts predict that Inspire Medical Systems will post 0.93 EPS for the current year.

Institutional Trading of Inspire Medical Systems

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP purchased a new position in shares of Inspire Medical Systems in the fourth quarter valued at approximately $203,929,000. Wasatch Advisors LP grew its holdings in shares of Inspire Medical Systems by 7.2% in the second quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after purchasing an additional 110,288 shares in the last quarter. Morgan Stanley increased its stake in Inspire Medical Systems by 179.5% during the 4th quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock worth $116,188,000 after buying an additional 809,121 shares during the period. Deerfield Management Company L.P. increased its stake in Inspire Medical Systems by 648.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after buying an additional 907,694 shares during the period. Finally, State Street Corp lifted its holdings in Inspire Medical Systems by 2.3% during the 2nd quarter. State Street Corp now owns 1,030,902 shares of the company’s stock worth $133,780,000 after buying an additional 22,843 shares in the last quarter. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.